1. In Vivo Pre-clinical characterization of a Novel Series of FGFR2 Selective Inhibitors with Potency Against Clinically Relevant Mutations. (October 2022) Authors: Fischer, J.; Bouhana, K.; Chicarelli, M.J.; Dahlke, J.; Fell, B.; Fulton, J.; Guarnieri, A.; Haygood, L.; Jalluri, R.; Johnson, A.; McLean, B.; Max, M.; Rieger, R.; Robinson, J.; Rodriguez, M.; Sullivan, F.; Wang, Y.; Winski, S.; Zhou, Y. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S81 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PO-0945: The impact of surgery type in breast cancer patients that received neoadjuvant chemotherapy. (November 2020) Authors: Marta, G.; Pereira, A.; Oliveira, J.; Roberto, F. José; Max, M. Journal: Radiotherapy and oncology Issue: Volume 152(2020)Supplement 1 Page Start: S504 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗